Место b-адреноблокаторов в новом пересмотре Европейских рекомендаций по диагностике и лечению артериальной гипертонии 2018 г. при терапии пациентов с коморбидной патологией
Место b-адреноблокаторов в новом пересмотре Европейских рекомендаций по диагностике и лечению артериальной гипертонии 2018 г. при терапии пациентов с коморбидной патологией
Остроумова О.Д., Кочетков А.И. Место b-адреноблокаторов в новом пересмотре Европейских рекомендаций по диагностике и лечению артериальной гипертонии 2018 г. при терапии пациентов с коморбидной патологией. Системные гипертензии. 2018; 15 (4): 8–16. DOI: 10.26442/2075082X.2018.4.000028
________________________________________________
Ostroumova O.D., Kochetkov A.I. The role of b-blockers in the new revision of the 2018 European guidelines for the diagnosis and treatment of arterial hypertension in the patients with comorbidities. Systemic Hypertension. 2018; 15 (4): 8–16. DOI: 10.26442/2075082X.2018.4.000028
Место b-адреноблокаторов в новом пересмотре Европейских рекомендаций по диагностике и лечению артериальной гипертонии 2018 г. при терапии пациентов с коморбидной патологией
Остроумова О.Д., Кочетков А.И. Место b-адреноблокаторов в новом пересмотре Европейских рекомендаций по диагностике и лечению артериальной гипертонии 2018 г. при терапии пациентов с коморбидной патологией. Системные гипертензии. 2018; 15 (4): 8–16. DOI: 10.26442/2075082X.2018.4.000028
________________________________________________
Ostroumova O.D., Kochetkov A.I. The role of b-blockers in the new revision of the 2018 European guidelines for the diagnosis and treatment of arterial hypertension in the patients with comorbidities. Systemic Hypertension. 2018; 15 (4): 8–16. DOI: 10.26442/2075082X.2018.4.000028
В обзоре с позиций новейших Европейских рекомендаций по диагностике и лечению артериальной гипертонии рассматривается роль высокоселективных b-адреноблокаторов и прежде всего эталонного представителя данного класса препаратов бисопролола в схемах антигипертензивной терапии у коморбидных пациентов с артериальной гипертонией. С точки зрения доказательной медицины обсуждаются преимущества применения бисопролола у больных с коморбидной ишемической болезнью сердца, хронической сердечной недостаточностью, фибрилляцией предсердий и патологией аорты. Представлены данные о целесообразности и возможности включения в терапию высокоселективных b-адреноблокаторов у пациентов с хронической обструктивной болезнью легких, периферическим атеросклерозом, сахарным диабетом и сексуальной дисфункцией.
The review from the standpoint of the newest European guidelines for the diagnosis and treatment of arterial hypertension discusses the role of highly selective b-blockers and, above all, the superior member of these drugs – bisoprolol in blood pressure lowering therapy in comorbid patients with arterial hypertension. In terms of evidence-based medicine, the benefits of bisoprolol in patients with comorbid coronary heart disease, chronic heart failure, atrial fibrillation, and aortic pathology are discussed. The data on the feasibility and the possibility of including in the therapy highly selective b-adrenergic blockers in patients with chronic obstructive pulmonary disease, peripheral artery disease, diabetes and sexual dysfunction are presented.
1. Wang J, Ma JJ, Liu J et al. Prevalence and Risk Factors of Comorbidities among Hypertensive Patients in China. Int J Med Sci 2017; 14 (3): 201–12. DOI: 10.7150/ijms.16974
2. Kraemer HC. Statistical issues in assessing comorbidity. Stat Med 1995; 14: 721–3.
3. Van den Akker M. Comorbidity or multimorbidity: what’s in a name? A review of the literature. Eur J Gen Pract 1996; 2 (2): 65–70.
4. Лазебник Л.Б. Старение и полиморбидность. Consilium Medicum. 2005; 7 (12): 993–6. / Lazebnik L.B. Starenie i polimorbidnost'. Consilium Medicum. 2005; 7 (12): 993–6. [in Russian]
5. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 1993; 31 (2): 141–54.
6. Noh J, Kim HC, Shin A et al. Prevalence of Comorbidity among People with Hypertension: The Korea National Health and Nutrition Examination Survey 2007–2013. Korean Circ J 2016; 46 (5): 672–80. DOI: 10.4070/kcj.2016.46.5.672
7. Williams B, Mancia G, Spiering W et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the ESC and ESH. Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
8. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the ESH and of the ESC. J Hypertens 2013; 31: 1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc
9. Yusuf S, Hawken S, Ounpuu S et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937–52. DOI: 10.1016/S0140-6736(04)17018-9
10. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383 (9932): 1899–911. DOI: 10.1016/S0140-6736(14)60685-1
11. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387 (10022): 957–67. DOI: 10.1016/S0140-6736(15)01225-8
12. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665. DOI: 10.1136/bmj.b1665
13. Клиническая фармакология. Учебник. Под ред. В.Г.Кукеса. 3-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2006. / Klinicheskaia farmakologiia. Uchebnik. Pod red. V.G.Kukesa. 3-e izd., pererab. i dop. M.: GEOTAR-Media, 2006. [in Russian]
14. Лукина Ю.В, Марцевич С.Ю. Бисопролол – высокоселективный бета-адреноблокатор с позиции доказательной медицины. Рацион. фармакотерапия в кардиологии. 2010; 6 (1): 103–7. / Lukina Yu.V, Martsevich S.Yu. Bisoprolol – vysokoselektivnyi beta-adrenoblokator s pozitsii dokazatel'noi meditsiny. Ratsion. farmakoterapiia v kardiologii. 2010; 6 (1): 103–7. [in Russian]
15. Оганезова Л.Г. Бисопролол – оптимальный бета-адреноблокатор для лечения сердечно-сосудистых заболеваний. Рус. мед. журн. 2012; 11: 560–2. / Oganezova L.G. Bisoprolol – optimal'nyi beta-adrenoblokator dlia lecheniia serdechno-sosudistykh zabolevanii. Rus. med. zhurn. 2012; 11: 560–2. [in Russian]
16. Wellstein A, Palm D, Belz G. Affinity and selectivity of the b-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol 1985; 8 (Suppl. 2) 11: 36–40. DOI: 10.1097/00005344-198511001-00006
17. De Muinck ED, Buchner-Moell D, van de Ven LLM, Lie KI; on behalf of the MIRSA Study Group. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina Oectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19: 870–5.
18. Poldermans D, Boersma E, Bax JJ et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341 (24): 1789–94. DOI: 10.1056/NEJM199912093412402
19. Ponikowski P, Voors AA, Anker SD et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the ESC Developed with the special contribution of the HFA of the ESC. Eur Heart J 2016; 37 (27): 2129–200. DOI: 10.1093/eurheartj/ehw128
20. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulatio 1994; 90 (4): 1765–73. DOI: 10.1161/01.CIR.90.4.1765
21. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9–13. DOI: 10.1016/S0140-6736(98)11181-9
22. Willenheimer R, van Veldhuisen DJ, Silke B et al.; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112 (16): 2426–35. DOI: 10.1161/CIRCULATIONAHA.105.582320
23. Lip GY Atrial Fibrillation in Patients With Hypertension: Trajectories of Risk Factors in Yet Another Manifestation of Hypertensive Target Organ Damage. Hypertension 2016; 68 (3): 544–5. DOI: 10.1161/HYPERTENSIONAHA.116.07901
24. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet 2016; 388 (10046): 806–17. DOI: 10.1016/S0140-6736(16)31257-0
25. Marazzi G, Iellamo F, Volterrani M et al. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. Am J Cardiol 2011; 107 (2): 215–9. DOI: 10.1016/j.amjcard.2010.08.062
26. Negreva MN, Penev AP. Effect of selective beta-blockade with bisoprolol in the treatment of recentonset atrial fibrillation. Folia Med (Plovdiv) 2012; 54 (2): 27–31. DOI: 10.2478/v10153-011-0085-7
27. Ishiguro H, Ikeda T, Abe A et al. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J 2008; 49 (3): 281–93.
28. Farsang CK, Kiss I, Tykarski A, Narkiewicz K. Treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD). Eur Society Hypertens Sci Newsletter 2016; 17: 62.
29. Rutten FH, Zuithoff NP, Hak E et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170 (10): 880–7. DOI: 10.1001/archinternmed.2010.112
30. Coiro S, Girerd N, Rossignol P et al. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 2017; 19: 271–9. DOI: 10.1002/ejhf.647
31. Напалков Д.А., Панферов А.С. Особенности течения сердечно-сосудистых заболеваний и принципы выбора рациональной антигипертензивной терапии у больных хронической обструктивной болезнью легких. Системные гипертензии. 2013; 3: 77–9. / Napalkov D.A., Panferov A.S. The specific features of cardiovascular diseases and the principles of choice of rational antihypertensive therapy for patients with chronic obstructive pulmonary disease. Systemic Hypertension. 2013; 3: 77–9. [in Russian]
32. Salpeter S, Ormiston T, Salpeter E. Cardioselective betablocker use in patients with reactive airway disease: a metaanalysis. Ann Intern Med 2002; 137: 715–25.
33. Kazani S, Israel E. Treatment with beta blockers in people with COPD. BMJ 2011; 342: d2655. DOI: 10.1136/bmj.d2655
34. Dorow P, Bethge H, Tönnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143–7.
35. Düngen HD, Apostolovic S, Inkrot S et al.; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011; 13 (6): 670–80. DOI: 10.1093/eurjhf/hfr020
36. Кукес В.Г., Остроумова О.Д., Мамаев В.И. и др. Эффективность и безопасность различных бета-блокаторов у пациентов с изолированной систолической гипертонией и сопутствующими сахарным диабетом и обструктивными заболеваниями легких. Терапевтический архив. 2003; 8: 43–7. / Kukes V.G, Ostroumova O.D., Mamaev V.I. i dr. Effektivnost' i bezopasnost' razlichnykh beta-blokatorov u patsientov s izolirovannoi sistolicheskoi gipertoniei i soputstvuiushchimi sakharnym diabetom i obstruktivnymi zabolevaniiami legkikh. Therapeutic archive. 2003; 8: 43–7. [in Russian]
37. Aboyans V, Ricco JB, Bartelink MEL et al.; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the ESVS: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the ESO The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the ESC and of the ESVS. Eur Heart J 2018; 39 (9): 763–816. DOI: 10.1093/eurheartj/ehx095
38. Catapano AL, Graham I, De Backer G et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999–58. DOI: 10.1093/eurheartj/ehw272
39. Criqui МН, Aboyans V. Epidemiology of Peripheral Artery Disease. Circ Res 2015; 116: 1509–26. DOI: 10.1161/CIRCRESAHA.116.303849
40. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286 (11): 1317–24. DOI: 10.1001/jama.286.11.1317
41. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009; 38: 66–70. DOI: 10.1016/j.ejvs.2009.02.019
42. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151 (9): 1769–76. DOI: 10.1001/archinte.1991.00400090063012
43. Van de Ven LL, Van Leeuwen JT, Smit AJ. The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa 1994; 23 (4): 357–62.
44. Soga Y, Iida O, Suzuki K et al. Clinical impact of bisoprolol versus carvedilol in patients undergoing femoropopliteal stenting. J Atheroscler Thromb 2014; 21 (7): 691–702. DOI: 10.5551/jat.21121
45. Fogari R, Zoppi A, Tettamanti F et al. b-Blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): S76–S80.
46. Wijkman M, Länne T, Engvall J et al. Masked nocturnal hypertension--a novel marker of risk in type 2 diabetes. Diabetologia 2009; 52 (7): 1258–64. DOI: 10.1007/s00125-009-1369-9
47. Pavlyuk EA, Sirenko YN, Rekovets OL, Savitskiy S. The impact of beta-adrenergic blockers atenolol, carvedilol and bisoprolol on the insulinresistance in patients with arterial hypertension and metabolic syndrome: Abstract P4854. Eur Heart J 2007; 28 (Suppl. 1): 870.
48. Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013; 381 (9861): 153–65. DOI: 10.1016/S0140-6736(12)60520-0
49. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58 (13): 1378–85. DOI: 10.1016/j.jacc.2011.06.024
50. Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992; 18 (4): 325–31. DOI: 10.1080/00926239208412857
51. Лоран О.Б., Сегал А.С., Верткин А.Л. и др. Клиническая эффективность и влияние b-адреноблокаторов на копулятивную функцию у больных артериальной гипертензией. Кардиология. 2002; 9: 39–42. / Loran O.B., Segal A.S., Vertkin A.L. i dr. Klinicheskaia effektivnost' i vliianie b-adrenoblokatorov na kopuliativnuiu funktsiiu u bol'nykh arterial'noi gipertenziei. Kardiologiia. 2002; 9: 39–42. [in Russian]
________________________________________________
1. Wang J, Ma JJ, Liu J et al. Prevalence and Risk Factors of Comorbidities among Hypertensive Patients in China. Int J Med Sci 2017; 14 (3): 201–12. DOI: 10.7150/ijms.16974
2. Kraemer HC. Statistical issues in assessing comorbidity. Stat Med 1995; 14: 721–3.
3. Van den Akker M. Comorbidity or multimorbidity: what’s in a name? A review of the literature. Eur J Gen Pract 1996; 2 (2): 65–70.
4. Lazebnik L.B. Starenie i polimorbidnost'. Consilium Medicum. 2005; 7 (12): 993–6. [in Russian]
5. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 1993; 31 (2): 141–54.
6. Noh J, Kim HC, Shin A et al. Prevalence of Comorbidity among People with Hypertension: The Korea National Health and Nutrition Examination Survey 2007–2013. Korean Circ J 2016; 46 (5): 672–80. DOI: 10.4070/kcj.2016.46.5.672
7. Williams B, Mancia G, Spiering W et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the ESC and ESH. Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
8. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the ESH and of the ESC. J Hypertens 2013; 31: 1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc
9. Yusuf S, Hawken S, Ounpuu S et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (9438): 937–52. DOI: 10.1016/S0140-6736(04)17018-9
10. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383 (9932): 1899–911. DOI: 10.1016/S0140-6736(14)60685-1
11. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387 (10022): 957–67. DOI: 10.1016/S0140-6736(15)01225-8
12. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665. DOI: 10.1136/bmj.b1665
13. Klinicheskaia farmakologiia. Uchebnik. Pod red. V.G.Kukesa. 3-e izd., pererab. i dop. M.: GEOTAR-Media, 2006. [in Russian]
14. Lukina Yu.V, Martsevich S.Yu. Bisoprolol – vysokoselektivnyi beta-adrenoblokator s pozitsii dokazatel'noi meditsiny. Ratsion. farmakoterapiia v kardiologii. 2010; 6 (1): 103–7. [in Russian]
15. Oganezova L.G. Bisoprolol – optimal'nyi beta-adrenoblokator dlia lecheniia serdechno-sosudistykh zabolevanii. Rus. med. zhurn. 2012; 11: 560–2. [in Russian]
16. Wellstein A, Palm D, Belz G. Affinity and selectivity of the b-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol 1985; 8 (Suppl. 2) 11: 36–40. DOI: 10.1097/00005344-198511001-00006
17. De Muinck ED, Buchner-Moell D, van de Ven LLM, Lie KI; on behalf of the MIRSA Study Group. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina Oectoris (MIRSA). J Cardiovasc Pharmacol 1992; 19: 870–5.
18. Poldermans D, Boersma E, Bax JJ et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341 (24): 1789–94. DOI: 10.1056/NEJM199912093412402
19. Ponikowski P, Voors AA, Anker SD et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the ESC Developed with the special contribution of the HFA of the ESC. Eur Heart J 2016; 37 (27): 2129–200. DOI: 10.1093/eurheartj/ehw128
20. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulatio 1994; 90 (4): 1765–73. DOI: 10.1161/01.CIR.90.4.1765
21. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9–13. DOI: 10.1016/S0140-6736(98)11181-9
22. Willenheimer R, van Veldhuisen DJ, Silke B et al.; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112 (16): 2426–35. DOI: 10.1161/CIRCULATIONAHA.105.582320
23. Lip GY Atrial Fibrillation in Patients With Hypertension: Trajectories of Risk Factors in Yet Another Manifestation of Hypertensive Target Organ Damage. Hypertension 2016; 68 (3): 544–5. DOI: 10.1161/HYPERTENSIONAHA.116.07901
24. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet 2016; 388 (10046): 806–17. DOI: 10.1016/S0140-6736(16)31257-0
25. Marazzi G, Iellamo F, Volterrani M et al. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. Am J Cardiol 2011; 107 (2): 215–9. DOI: 10.1016/j.amjcard.2010.08.062
26. Negreva MN, Penev AP. Effect of selective beta-blockade with bisoprolol in the treatment of recentonset atrial fibrillation. Folia Med (Plovdiv) 2012; 54 (2): 27–31. DOI: 10.2478/v10153-011-0085-7
27. Ishiguro H, Ikeda T, Abe A et al. Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J 2008; 49 (3): 281–93.
28. Farsang CK, Kiss I, Tykarski A, Narkiewicz K. Treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD). Eur Society Hypertens Sci Newsletter 2016; 17: 62.
29. Rutten FH, Zuithoff NP, Hak E et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170 (10): 880–7. DOI: 10.1001/archinternmed.2010.112
30. Coiro S, Girerd N, Rossignol P et al. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 2017; 19: 271–9. DOI: 10.1002/ejhf.647
31. Napalkov D.A., Panferov A.S. The specific features of cardiovascular diseases and the principles of choice of rational antihypertensive therapy for patients with chronic obstructive pulmonary disease. Systemic Hypertension. 2013; 3: 77–9. [in Russian]
32. Salpeter S, Ormiston T, Salpeter E. Cardioselective betablocker use in patients with reactive airway disease: a metaanalysis. Ann Intern Med 2002; 137: 715–25.
33. Kazani S, Israel E. Treatment with beta blockers in people with COPD. BMJ 2011; 342: d2655. DOI: 10.1136/bmj.d2655
34. Dorow P, Bethge H, Tönnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31 (2): 143–7.
35. Düngen HD, Apostolovic S, Inkrot S et al.; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011; 13 (6): 670–80. DOI: 10.1093/eurjhf/hfr020
36. Kukes V.G, Ostroumova O.D., Mamaev V.I. i dr. Effektivnost' i bezopasnost' razlichnykh beta-blokatorov u patsientov s izolirovannoi sistolicheskoi gipertoniei i soputstvuiushchimi sakharnym diabetom i obstruktivnymi zabolevaniiami legkikh. Therapeutic archive. 2003; 8: 43–7. [in Russian]
37. Aboyans V, Ricco JB, Bartelink MEL et al.; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the ESVS: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the ESO The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the ESC and of the ESVS. Eur Heart J 2018; 39 (9): 763–816. DOI: 10.1093/eurheartj/ehx095
38. Catapano AL, Graham I, De Backer G et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999–58. DOI: 10.1093/eurheartj/ehw272
39. Criqui МН, Aboyans V. Epidemiology of Peripheral Artery Disease. Circ Res 2015; 116: 1509–26. DOI: 10.1161/CIRCRESAHA.116.303849
40. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286 (11): 1317–24. DOI: 10.1001/jama.286.11.1317
41. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009; 38: 66–70. DOI: 10.1016/j.ejvs.2009.02.019
42. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151 (9): 1769–76. DOI: 10.1001/archinte.1991.00400090063012
43. Van de Ven LL, Van Leeuwen JT, Smit AJ. The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa 1994; 23 (4): 357–62.
44. Soga Y, Iida O, Suzuki K et al. Clinical impact of bisoprolol versus carvedilol in patients undergoing femoropopliteal stenting. J Atheroscler Thromb 2014; 21 (7): 691–702. DOI: 10.5551/jat.21121
45. Fogari R, Zoppi A, Tettamanti F et al. b-Blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol 1990; 16 (Suppl. 5): S76–S80.
46. Wijkman M, Länne T, Engvall J et al. Masked nocturnal hypertension--a novel marker of risk in type 2 diabetes. Diabetologia 2009; 52 (7): 1258–64. DOI: 10.1007/s00125-009-1369-9
47. Pavlyuk EA, Sirenko YN, Rekovets OL, Savitskiy S. The impact of beta-adrenergic blockers atenolol, carvedilol and bisoprolol on the insulinresistance in patients with arterial hypertension and metabolic syndrome: Abstract P4854. Eur Heart J 2007; 28 (Suppl. 1): 870.
48. Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013; 381 (9861): 153–65. DOI: 10.1016/S0140-6736(12)60520-0
49. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58 (13): 1378–85. DOI: 10.1016/j.jacc.2011.06.024
50. Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992; 18 (4): 325–31. DOI: 10.1080/00926239208412857
51. Loran O.B., Segal A.S., Vertkin A.L. i dr. Klinicheskaia effektivnost' i vliianie b-adrenoblokatorov na kopuliativnuiu funktsiiu u bol'nykh arterial'noi gipertenziei. Kardiologiia. 2002; 9: 39–42. [in Russian]
Авторы
О.Д.Остроумова*, А.И.Кочетков
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1 *ostroumova.olga@mail.ru
________________________________________________
O.D.Ostroumova*, A.I.Kochetkov
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1 *ostroumova.olga@mail.ru